Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Bmal1-ethanol based diet and liver injury (Study ST000674)

C18 NEGATIVE ION MODE (Analysis AN001034)

Metabolite	Structure	F1	F2
PC 38:7; [M-Ac-H]-@5.70	ME186065	0.72	1.28
lysoPE 18:1; [M-H]-@1.81	ME186196	0.72	1.28
PC 38:5; [M-Ac-H]-@6.49	ME186062	0.72	1.28
PS 40:7; [M-H]-@5.32	ME186189	0.73	1.27
lysoPE 20:4; [M-H]-@1.29	ME186203	0.73	1.27
PC 34:0; [M-Ac-H]-@6.79	ME186036	0.73	1.27
PG 38:7; [M-H]-@4.36	ME186163	0.74	1.26
PC 41:6; [M-Ac-H]-@7.26	ME186075	0.74	1.26
PE 36:6; [M-H]-@5.56	ME186108	0.74	1.26
CL 82:1; [M-2H](2-)@8.46	ME186002	0.76	1.24
FFA(22:0)	ME186011	0.75	1.25
PE 34:3; [M-H]-@5.98	ME186093	0.75	1.25
PC 42:4; [M-Ac-H]-@8.18	ME186078	0.71	1.29
PE 40:4; [M-H]-@7.64	ME186132	0.70	1.30
FFA(24:0)	ME186015	0.70	1.30
PE 40:4; [M-H]-@7.35	ME186131	0.70	1.30
PC 36:5; [M-Ac-H]-@5.87	ME186050	0.67	1.33
PC 44:4; [M-Ac-H]-@9.03	ME186084	0.67	1.33
PE 42:7; [M-H]-@7.00	ME186142	0.68	1.32
PC 38:1; [M-Ac-H]-@8.24	ME186057	0.68	1.32
PE 40:3; [M-H]-@7.86	ME186130	0.68	1.32
PG 34:3; [M-H]-@4.70	ME186148	0.69	1.31
PG 36:4; [M-H]-@5.40	ME186154	0.69	1.31
lysoPE 17:1; [M-H]-@1.50	ME186194	0.59	1.41
lysoPE 20:1; [M-H]-@2.67	ME186200	0.57	1.43
PE 39:4; [M-H]-@7.23	ME186125	0.57	1.43
PC 36:6; [M-Ac-H]-@5.54	ME186051	0.65	1.35
CerP 34:1; [M-H]-@6.03	ME186003	0.65	1.35
PC 32:1; [M-Ac-H]-@6.25	ME186032	0.65	1.35
PC 34:3; [M-Ac-H]-@5.94	ME186040	0.64	1.36
PC 40:3; [M-Ac-H]-@7.91	ME186070	0.64	1.36
FFA(22:1)	ME186012	0.63	1.37
PE 38:7; [M-H]-@5.75	ME186123	0.63	1.37
PC 32:2; [M-Ac-H]-@5.78	ME186033	0.62	1.38
PE 34:4; [M-H]-@5.56	ME186094	0.62	1.38
PE 32:1; [M-H]-@6.26	ME186087	0.60	1.40
PE 32:2; [M-H]-@5.78	ME186088	0.61	1.39
CL 66:3; [M-2H](2-)@5.99	ME185989	0.61	1.39
PC 40:2; [M-Ac-H]-@8.29	ME186069	0.61	1.39
PC 44:12; [M-Ac-H]-@5.69	ME186083	0.50	1.50
PE 36:5; [M-H]-@5.88	ME186107	0.52	1.48
PC 42:6; [M-Ac-H]-@7.59	ME186080	0.34	1.66
lysoPE 20:0; [M-H]-@3.47	ME186199	0.46	1.54
lysoPE 20:5; [M-H]-@1.02	ME186204	0.44	1.56
PG 32:1; [M-H]-@5.23	ME186145	0.42	1.58
lysoPE 16:1; [M-H]-@1.22	ME186192	0.39	1.61
PG 42:11; [M-H]-@4.13	ME186170	0.40	1.60
CL 72:7; [M-2H](2-)@9.06	ME185994	1.09	0.91
PG 44:12; [M-H]-@4.41	ME186176	1.09	0.91
plasmenyl-PE 40:5; [M-H]-@6.99	ME186226	1.08	0.92
PC 35:1; [M-Ac-H]-@7.29	ME186042	1.08	0.92
PC 36:3; [M-Ac-H]-@6.56	ME186048	1.08	0.92
plasmenyl-PE 42:5; [M-H]-@7.91	ME186230	1.13	0.87
plasmenyl-PE 38:3; [M-H]-@7.61	ME186219	1.12	0.88
PC 38:4; [M-Ac-H]-@6.76	ME186060	1.12	0.88
PC 38:4; [M-Ac-H]-@7.04	ME186061	1.12	0.88
plasmenyl-PE 34:0; [M-H]-@7.28	ME186208	1.11	0.89
PG 40:8; [M-H]-@4.54	ME186167	1.11	0.89
PE 42:8; [M-H]-@6.57	ME186143	1.11	0.89
PE 35:4; [M-H]-@6.08	ME186099	1.11	0.89
PC 35:3; [M-Ac-H]-@6.23	ME186044	1.11	0.89
CL 72:5; [M-2H](2-)@9.47	ME185992	1.11	0.89
FFA(20:2)	ME186010	1.11	0.89
plasmenyl-PE 40:6; [M-H]-@7.20	ME186228	1.10	0.90
plasmenyl-PE 40:4; [M-H]-@7.79	ME186225	1.10	0.90
PE 40:6; [M-H]-@6.86	ME186135	1.10	0.90
PA 42:7; [M-H]-@5.78	ME186029	1.10	0.90
PE 38:1; [M-H]-@7.98	ME186114	1.10	0.90
plasmenyl-PE 34:1; [M-H]-@7.26	ME186209	1.06	0.94
PE 38:5; [M-H]-@6.55	ME186121	1.06	0.94
PE 36:3; [M-H]-@5.93	ME186104	1.06	0.94
PC 42:9; [M-Ac-H]-@6.12	ME186082	1.06	0.94
PC 37:6; [M-Ac-H]-@5.91	ME186056	1.06	0.94
lysoPE 22:4; [M-H]-@1.79	ME186205	1.06	0.94
CL 72:6; [M-2H](2-)@9.29	ME185993	1.06	0.94
lysoPE 17:0; [M-H]-@2.08	ME186193	1.06	0.94
PI 34:2; [M-H]-@5.23	ME186177	1.07	0.93
PC 37:2; [M-Ac-H]-@7.43	ME186053	1.07	0.93
PE 36:2; [M-H]-@7.01	ME186103	1.07	0.93
PS 38:6; [M-H]-@5.23	ME186187	1.04	0.96
PC 40:8; [M-Ac-H]-@5.92	ME186074	1.04	0.96
PC 36:4; [M-Ac-H]-@6.22	ME186049	1.04	0.96
lysoPE 19:0; [M-H]-@2.87	ME186198	1.04	0.96
PA 40:4; [M-H]-@6.13	ME186025	1.04	0.96
PI 36:3; [M-H]-@5.39	ME186179	1.05	0.95
PC 37:1; [M-Ac-H]-@7.85	ME186052	1.05	0.95
PG 38:2; [M-H]-@6.15	ME186156	1.05	0.95
plasmenyl-PE 42:6; [M-H]-@7.77	ME186231	1.03	0.97
plasmenyl-PE 38:4; [M-H]-@7.30	ME186221	1.03	0.97
FFA(22:2)	ME186013	1.03	0.97
PI 38:4; [M-H]-@5.81	ME186182	1.03	0.97
PS 38:4; [M-H]-@5.97	ME186186	1.02	0.98
PG 38:4; [M-H]-@5.40	ME186158	1.02	0.98
PE 37:5; [M-H]-@6.22	ME186112	1.02	0.98
PE 36:1; [M-H]-@7.49	ME186102	1.02	0.98
FFA(24:1)	ME186016	1.02	0.98
PE 35:3; [M-H]-@6.26	ME186098	1.02	0.98
plasmenyl-PE 38:6; [M-H]-@6.60	ME186223	1.01	0.99
PI 36:2; [M-H]-@5.89	ME186178	1.01	0.99
PG 38:5; [M-H]-@5.06	ME186161	1.01	0.99
PE 40:2; [M-H]-@8.04	ME186129	1.01	0.99
PC 32:0; [M-Ac-H]-@6.78	ME186031	1.01	0.99
PC 34:0; [M-Ac-H]-@7.50	ME186037	1.01	0.99
PE 38:3; [M-H]-@7.28	ME186118	1.00	1.00
PC 39:7; [M-Ac-H]-@6.06	ME186068	1.00	1.00
PC 35:4; [M-Ac-H]-@6.09	ME186045	1.00	1.00
CL 68:1; [M-2H](2-)@7.23	ME185990	1.00	1.00
IS PC 34:0;[M-Ac-H]-	ME186019	1.00	1.00
PC 42:2; [M-Ac-H]-@9.07	ME186077	0.99	1.01
FFA(18:0)	ME186005	0.99	1.01
PC 30:1; [M-Ac-H]-@5.60	ME186030	0.99	1.01
plasmenyl-PE 34:2; [M-H]-@6.77	ME186210	0.78	1.22
PC 34:1; [M-Ac-H]-@6.84	ME186038	0.78	1.22
PE 38:3; [M-H]-@6.61	ME186117	0.78	1.22
PE 32:0; [M-H]-@6.80	ME186086	0.77	1.23
PG 36:5; [M-H]-@4.49	ME186155	0.77	1.23
PE 39:3; [M-H]-@7.57	ME186124	0.79	1.21
PG 40:9; [M-H]-@4.20	ME186168	0.80	1.20
PS 36:4; [M-H]-@5.29	ME186185	0.80	1.20
PE 36:4; [M-H]-@6.23	ME186106	0.86	1.14
PE 41:6; [M-H]-@7.16	ME186139	0.86	1.14
PG 38:5; [M-H]-@5.51	ME186160	0.85	1.15
PC 38:6; [M-Ac-H]-@11.23	ME186063	0.85	1.15
Arachidonic acid	ME185988	0.85	1.15
lysoPE 18:2; [M-H]-@1.34	ME186197	0.85	1.15
PE 39:7; [M-H]-@6.08	ME186127	0.84	1.16
PC 36:1; [M-Ac-H]-@7.58	ME186046	0.84	1.16
PC 42:5; [M-Ac-H]-@7.75	ME186079	0.84	1.16
PC 38:2; [M-Ac-H]-@7.74	ME186058	0.83	1.17
PE 40:9; [M-H]-@5.54	ME186138	0.83	1.17
PG 34:2; [M-H]-@5.20	ME186147	0.82	1.18
lysoPE 16:0; [M-H]-@1.69	ME186191	0.82	1.18
lysoPE 20:2; [M-H]-@2.09	ME186201	0.82	1.18
PE 38:4; [M-H]-@7.03	ME186119	0.81	1.19
PE 33:1; [M-H]-@6.62	ME186089	0.81	1.19
PE 38:4; [M-H]-@6.71	ME186120	0.81	1.19
PE 42:4; [M-H]-@8.14	ME186141	0.87	1.13
CL 76:10; [M-2H](2-)@9.06	ME185998	0.87	1.13
PC 33:1; [M-Ac-H]-@6.59	ME186034	0.87	1.13
PI 36:4; [M-H]-@5.19	ME186180	0.88	1.12
PC 40:4; [M-Ac-H]-@7.59	ME186071	0.88	1.12
FFA(20:0)	ME186008	0.88	1.12
lysoPE 22:6; [M-H]-@1.24	ME186207	0.88	1.12
PG 42:7; [M-H]-@5.47	ME186171	0.90	1.10
lysoPE 18:0; [M-H]-@2.47	ME186195	0.90	1.10
PE 40:1; [M-H]-@8.48	ME186128	0.90	1.10
plasmenyl-PE 40:5; [M-H]-@7.61	ME186227	0.89	1.11
PG 42:10; [M-H]-@4.51	ME186169	0.89	1.11
PG 38:6; [M-H]-@4.70	ME186162	0.89	1.11
PE 40:5; [M-H]-@6.29	ME186133	0.89	1.11
PE 37:4; [M-H]-@6.70	ME186111	0.89	1.11
lysoPE 20:3; [M-H]-@1.60	ME186202	0.89	1.11
PC 39:6; [M-Ac-H]-@6.51	ME186067	0.89	1.11
PG 34:1; [M-H]-@5.80	ME186146	0.95	1.05
PE 38:6; [M-H]-@6.15	ME186122	0.95	1.05
PE 35:2; [M-H]-@6.75	ME186097	0.95	1.05
CL 74:9; [M-2H](2-)@8.99	ME185997	0.95	1.05
PC 39:4; [M-Ac-H]-@7.38	ME186066	0.95	1.05
PE 34:1; [M-H]-@6.86	ME186091	0.96	1.04
PC 42:10; [M-Ac-H]-@5.82	ME186076	0.96	1.04
PC 40:6; [M-Ac-H]-@6.84	ME186072	0.96	1.04
FFA(16:0)	ME186004	0.96	1.04
FFA(18:1)	ME186006	0.96	1.04
PA 40:7; [M-H]-@5.15	ME186028	0.98	1.02
plasmenyl-PE 34:3; [M-H]-@6.40	ME186211	0.97	1.03
PI 38:5; [M-H]-@5.32	ME186183	0.97	1.03
PE 40:8; [M-H]-@5.98	ME186137	0.97	1.03
PE 37:2; [M-H]-@7.24	ME186110	0.97	1.03
FFA(18:2)	ME186007	0.97	1.03
PE 36:3; [M-H]-@6.56	ME186105	0.97	1.03
PG 36:4; [M-H]-@4.95	ME186153	0.94	1.06
PE 36:0; [M-H]-@7.95	ME186100	0.94	1.06
PE 34:2; [M-H]-@6.41	ME186092	0.94	1.06
PC 42:7; [M-Ac-H]-@6.94	ME186081	0.94	1.06
PC 38:6; [M-Ac-H]-@6.14	ME186064	0.94	1.06
CL 76:11; [M-2H](2-)@9.01	ME185999	0.94	1.06
PC 36:2; [M-Ac-H]-@7.00	ME186047	0.94	1.06
PE 40:7; [M-H]-@6.39	ME186136	0.93	1.07
FFA(20:1)	ME186009	0.93	1.07
lysoPE 22:5; [M-H]-@1.58	ME186206	0.93	1.07
plasmenyl-PE 36:4; [M-H]-@6.69	ME186216	0.91	1.09
PE 42:1; [M-H]-@9.03	ME186140	0.91	1.09
CL 70:4; [M-2H](2-)@9.40	ME185991	0.91	1.09
PC 38:3; [M-Ac-H]-@7.30	ME186059	0.91	1.09
plasmenyl-PE 38:5; [M-H]-@6.77	ME186222	0.92	1.08
PE 38:2; [M-H]-@7.57	ME186115	0.92	1.08
PC 34:2; [M-Ac-H]-@6.35	ME186039	0.92	1.08
PC 40:7; [M-Ac-H]-@6.28	ME186073	0.92	1.08
plasmenyl-PE 38:4; [M-H]-@5.89	ME186220	1.22	0.78
plasmenyl-PE 36:3; [M-H]-@7.00	ME186215	1.22	0.78
CL 80:15; [M-2H](2-)@9.10	ME186001	1.22	0.78
PG 40:5; [M-H]-@5.59	ME186164	1.22	0.78
PC 37:4; [M-Ac-H]-@6.67	ME186055	1.20	0.80
PS 42:10; [M-H]-@4.77	ME186190	1.20	0.80
plasmenyl-PE 38:2; [M-H]-@8.00	ME186218	1.15	0.85
PE 38:2; [M-H]-@7.02	ME186116	1.15	0.85
PG 40:7; [M-H]-@4.96	ME186166	1.15	0.85
PS 40:6; [M-H]-@5.91	ME186188	1.18	0.82
PS 36:2; [M-H]-@5.83	ME186184	1.18	0.82
PE 37:1; [M-H]-@7.70	ME186109	1.18	0.82
PE 36:1; [M-H]-@6.96	ME186101	1.18	0.82
PC 34:4; [M-Ac-H]-@5.67	ME186041	1.18	0.82
PA 40:6; [M-H]-@5.64	ME186027	1.18	0.82
FFA(24:2)	ME186017	1.18	0.82
PA 34:1; [M-H]-@5.66	ME186020	1.18	0.82
PG 40:6; [M-H]-@5.37	ME186165	1.19	0.81
PE 33:2; [M-H]-@6.07	ME186090	1.19	0.81
PE 35:0; [M-H]-@7.64	ME186095	1.19	0.81
plasmenyl-PE 40:3; [M-H]-@8.01	ME186224	1.17	0.83
PI 38:3; [M-H]-@6.10	ME186181	1.17	0.83
CL 74:8; [M-2H](2-)@9.13	ME185996	1.17	0.83
PG 36:3; [M-H]-@5.35	ME186152	1.17	0.83
PC 35:2; [M-Ac-H]-@6.76	ME186043	1.16	0.84
PE 40:5; [M-H]-@7.23	ME186134	1.16	0.84
PG 36:2; [M-H]-@5.85	ME186150	1.33	0.67
PG 36:2; [M-H]-@6.06	ME186151	1.33	0.67
PA 38:2; [M-H]-@6.38	ME186022	1.30	0.70
PA 38:4; [M-H]-@5.50	ME186023	1.30	0.70
plasmenyl-PE 38:1; [M-H]-@8.19	ME186217	1.31	0.69
PE 37:6; [M-H]-@6.01	ME186113	1.31	0.69
PG 38:3; [M-H]-@5.74	ME186157	1.31	0.69
PG 42:8; [M-H]-@5.16	ME186172	1.32	0.68
plasmenyl-PE 42:4; [M-H]-@8.23	ME186229	1.32	0.68
PC 37:3; [M-Ac-H]-@6.85	ME186054	1.24	0.76
PG 42:9; [M-H]-@4.81	ME186173	1.24	0.76
PE 35:1; [M-H]-@7.22	ME186096	1.25	0.75
PG 38:4; [M-H]-@6.04	ME186159	1.25	0.75
plasmenyl-PE 36:2; [M-H]-@5.93	ME186213	1.28	0.72
PA 38:5; [M-H]-@5.28	ME186024	1.28	0.72
PG 32:0; [M-H]-@5.74	ME186144	1.28	0.72
plasmenyl-PE 36:2; [M-H]-@7.36	ME186214	1.26	0.74
FFA(22:3)	ME186014	1.26	0.74
CL 72:8; [M-2H](2-)@8.87	ME185995	1.26	0.74
CL 80:10; [M-2H](2-)@6.40	ME186000	1.26	0.74
plasmenyl-PE 36:1; [M-H]-@7.80	ME186212	1.27	0.73
PA 36:3; [M-H]-@5.32	ME186021	1.27	0.73
PC 33:2; [M-Ac-H]-@6.16	ME186035	1.27	0.73
FFA(24:3)	ME186018	1.56	0.44
PA 40:5; [M-H]-@6.04	ME186026	1.40	0.60
PE 39:6; [M-H]-@6.57	ME186126	1.37	0.63
PG 36:1; [M-H]-@6.46	ME186149	1.38	0.62
PG 44:11; [M-H]-@4.78	ME186175	1.49	0.51
PE 30:0; [M-H]-@6.16	ME186085	1.46	0.54
PG 44:10; [M-H]-@5.09	ME186174	1.46	0.54

Factors:

F1	Type:Bmal1 knockdown
F2	Type:control

Data matrix